Alembic Pharmaceuticals Ltd posted a healthy set of numbers for the July–September quarter (Q2 FY26), with consolidated net profit rising 21% year-on-year to ₹185 crore, compared to ₹153 crore a year earlier.

Revenue grew 16% to ₹1,910 crore from ₹1,648 crore in the corresponding period last year, reflecting broad-based momentum across business segments.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) increased 32% year-on-year to ₹315.3 crore, while operating margins expanded to 16.5% from 14.5% a year ago.

The company’s international business remained a key growth driver. US generics revenue grew 21% to ₹566 crore, with three new product launches during the quarter, while Ex-US international generics revenue jumped 31% to ₹392 crore.

Alembic also received six

See Full Page